CareDx, Inc (NASDAQ:CDNA) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its stake in shares of CareDx, Inc (NASDAQ:CDNA) by 2.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 511,922 shares of the company’s stock after acquiring an additional 12,442 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in CareDx were worth $10,960,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Plato Investment Management Ltd lifted its holdings in shares of CareDx by 34.1% in the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock valued at $116,000 after buying an additional 1,370 shares during the period. US Bancorp DE lifted its holdings in shares of CareDx by 907.5% in the 4th quarter. US Bancorp DE now owns 17,168 shares of the company’s stock valued at $368,000 after buying an additional 15,464 shares during the period. Bradley & Co. Private Wealth Management LLC acquired a new stake in shares of CareDx in the 4th quarter valued at approximately $269,000. Bank of New York Mellon Corp lifted its holdings in shares of CareDx by 3.9% in the 4th quarter. Bank of New York Mellon Corp now owns 145,270 shares of the company’s stock valued at $3,110,000 after buying an additional 5,502 shares during the period. Finally, Thompson Davis & CO. Inc. lifted its holdings in shares of CareDx by 6.3% in the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company’s stock valued at $344,000 after buying an additional 950 shares during the period.

Analyst Ratings Changes

CDNA has been the subject of several recent analyst reports. Stephens reissued an “overweight” rating and issued a $40.00 price target on shares of CareDx in a report on Thursday, February 27th. StockNews.com raised CareDx from a “hold” rating to a “buy” rating in a report on Wednesday, February 26th. HC Wainwright reduced their price target on CareDx from $26.00 to $25.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Finally, Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and dropped their price objective for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.83.

CareDx Stock Performance

CareDx stock opened at $19.32 on Friday. The stock has a fifty day moving average of $21.79 and a two-hundred day moving average of $23.95. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -7.16 and a beta of 1.95. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, topping the consensus estimate of $0.05 by $1.46. The company had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. On average, analysts forecast that CareDx, Inc will post -0.9 EPS for the current fiscal year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.